Thomas Sandgaard Sells 2,000 Shares of Zynex, Inc. (NASDAQ:ZYXI) Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $8.37, for a total value of $16,740.00. Following the completion of the sale, the chief executive officer now owns 14,605,662 shares of the company’s stock, valued at $122,249,390.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Thomas Sandgaard also recently made the following trade(s):

• On Monday, November 11th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $9.09, for a total value of $18,180.00.
• On Friday, November 8th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.77, for a total value of $17,540.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.67, for a total transaction of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Stock Down 5.1 %

Shares of Zynex stock traded down $0.44 during midday trading on Wednesday, hitting $8.13. The company’s stock had a trading volume of 110,766 shares, compared to its average volume of 170,433. The firm has a market capitalization of $258.94 million, a P/E ratio of 54.20 and a beta of 0.53. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The stock has a 50-day simple moving average of $8.22 and a 200-day simple moving average of $8.92.

Zynex (NASDAQ:ZYXI) last issued its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, sell-side analysts expect that Zynex, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

ZYXI has been the subject of a number of recent analyst reports. Royal Bank of Canada decreased their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright boosted their price target on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 25th.

Institutional Investors Weigh In On Zynex

A number of institutional investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System purchased a new stake in shares of Zynex during the first quarter worth $137,000. Vanguard Group Inc. raised its stake in shares of Zynex by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock worth $14,684,000 after purchasing an additional 6,097 shares in the last quarter. BOKF NA acquired a new stake in shares of Zynex during the 1st quarter valued at about $246,000. Hancock Whitney Corp grew its stake in shares of Zynex by 24.9% in the 1st quarter. Hancock Whitney Corp now owns 32,903 shares of the company’s stock valued at $407,000 after buying an additional 6,566 shares in the last quarter. Finally, Platte River Wealth Advisors LLC increased its holdings in Zynex by 200.0% in the second quarter. Platte River Wealth Advisors LLC now owns 30,000 shares of the company’s stock worth $280,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.